Lindbrook Capital LLC Has $1.11 Million Stake in Danaher Co. (NYSE:DHR)

Lindbrook Capital LLC decreased its position in Danaher Co. (NYSE:DHR) by 9.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,826 shares of the conglomerate’s stock after selling 517 shares during the period. Lindbrook Capital LLC’s holdings in Danaher were worth $1,108,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kovack Advisors Inc. grew its holdings in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after acquiring an additional 41 shares in the last quarter. Gilbert & Cook Inc. grew its holdings in shares of Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after acquiring an additional 42 shares in the last quarter. Grimes & Company Inc. grew its holdings in shares of Danaher by 0.6% in the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after acquiring an additional 43 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Danaher by 3.0% in the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after acquiring an additional 45 shares in the last quarter. Finally, Dakota Community Bank & Trust NA grew its holdings in shares of Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after acquiring an additional 45 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $210.97 on Thursday. The firm’s fifty day moving average price is $223.22 and its two-hundred day moving average price is $243.63. The stock has a market cap of $150.78 billion, a PE ratio of 39.96, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the firm earned $2.09 EPS. On average, equities analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is presently 24.24%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $277.00 price objective (down previously from $299.00) on shares of Danaher in a report on Thursday, January 30th. Wells Fargo & Company reduced their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Barclays reduced their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Raymond James reiterated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Finally, Jefferies Financial Group reduced their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.